Methylation-derived inflammatory measures and lung cancer risk and survival

Clinical Epigenetics

Table 4 Association between methylation-based CRP scores and risk of total lung cancer and NSCLC risk, overall and stratified by time to diagnosis, CLUE I/II cohort

	All lung cancers^a OR (95% CI)	Non-small cell lung cancer^b OR (95% CI)
CRP Score 1^c	0.76 (0.59, 0.99)	0.57 (0.40, 0.81)
Time to diagnosis ≤ 10 years	0.84 (0.56, 1.26)	0.57 (0.33, 0.97)
Time to diagnosis > 10 years	0.67 (0.47, 0.97)	0.53 (0.32, 0.88)
CRP Score 2^d	0.77 (0.61, 0.98)	0.62 (0.45, 0.84)
Time to diagnosis ≤ 10 years	0.79 (0.54, 1.17)	0.49 (0.28, 0.85)
Time to diagnosis > 10 years	0.73 (0.53, 1.02)	0.68 (0.46, 1.00)
CRP Score 3^e	0.79 (0.58, 1.07)	0.65 (0.44, 0.95)
Time to diagnosis ≤ 10 years	0.87 (0.53, 1.42)	0.64 (0.35, 1.18)
Time to diagnosis > 10 years	0.73 (0.49, 1.09)	0.62 (0.36, 1.05)

Bold OR and CI values indicate statistical significance
^a208 cases and 208 controls matched for age at blood draw, sex, smoking status, and model further adjusting for BMI, surrogate variables for batch effects, and a methylation-predicted pack-years smoked
^b150 cases and 150 controls matched for age at blood draw, sex, smoking status, and model further adjusting for BMI, surrogate variables for batch effects, and a methylation-predicted pack-years smoked. The matched pairs were kept within each stratum
^cCpG Score 1 is built using 54 CpG sites and OR results reported per 1 unit of SD of CpG Score 1 (SD 1)
^dCpG Score 2 is built using the top 10 highly cell-specific CpG sites and OR results reported per 1 unit of SD of CpG Score 2 (SD 1)
^eCpG Score 3 is built using the 10 modestly cell-specific CpG sites and OR results reported per 1 unit of SD of CpG Score 3 (SD 1)

ISSN: 1868-7083